Aligos Therapeutics has a one year low of $6.76 and a one year high of $46.80. The stock has a market capitalization of $43.65 million, a price-to-earnings ratio of -0.54 and a beta of 2.52.

SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel ...

16:07 EDT Aligos Therapeutics (ALGS) files to sell 6.25M shares of common stock for holders Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed ...

SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics ...

(MENAFN- GlobeNewsWire - Nasdaq) SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS,“Aligos”), a clinical ...

The latest price target for Aligos Therapeutics (NASDAQ:ALGS) was reported by HC Wainwright & Co. on March 31, 2025. The analyst firm set a price target for $70.00 expecting ALGS to rise to within ...

Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases. The company is dedicated to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...